ABSTRACT
On 10 June 2002, the main results of RENAISSANCE, RECOVER and RENEWAL were presented during a hot line session of the Working Group on Heart Failure of the ESC annual meeting in Oslo, Norway.5 In the same session, the results of a smaller study called ATTACH were also shown.6 ATTACH was a phase II, multicentre, randomized, double-blind, placebo-controlled pilot trial that aimed to evaluate the effects of infliximab in CHF patients with stable New York Heart Association (NYHA) class III or IV. This trial was also stopped prematurely.7,8 In contrast to the etanercept programme that involved 2048 randomized patients, ATTACH had recruited only 150 patients.
